<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03676010</url>
  </required_header>
  <id_info>
    <org_study_id>IB2009-DATECAN-1</org_study_id>
    <nct_id>NCT03676010</nct_id>
  </id_info>
  <brief_title>Definition for the Assessment of Time-to-event Endpoints in CANcer Trials (DATECAN-1)</brief_title>
  <acronym>DATECAN-1</acronym>
  <official_title>Definition for the Assessment of Time-to-event Endpoints in CANcer Trials (DATECAN-1) : Formal Consensus Method for the Development of Guidelines for Standardized Time-to-event Endpoints' Definitions in Cancer Clinical Trials</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Georges Francois Leclerc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Bergonié</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In randomised phase III cancer clinical trials, the most objectively defined and only
      validated time-to-event endpoint is overall survival (OS). The appearance of new types of
      treatments and the multiplication of lines of treatment have resulted in the use of surrogate
      endpoints for overall survival such as progression-free survival (PFS), or time-to-treatment
      failure. Their development is strongly influenced by the necessity of reducing clinical trial
      duration, cost and number of patients. However, while these endpoints are frequently used,
      they are often poorly defined and definitions can differ between trials which may limit their
      use as primary endpoints. Moreover, this variability of definitions can impact on the trial's
      results by affecting estimation of treatments' effects. The aim of the Definition for the
      Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project is to provide
      recommendations for standardised definitions of time-to-event endpoints in randomised cancer
      clinical trials.

      We will use a formal consensus methodology based on experts' opinions which will be obtained
      in a systematic manner.

      Definitions will be independently developed for several cancer sites, including pancreatic,
      breast, head and neck and colon cancer, as well as sarcomas and gastrointestinal stromal
      tumours (GISTs).

      The DATECAN project should lead to the elaboration of recommendations that can then be used
      as guidelines by researchers participating in clinical trials. This process should lead to a
      standardisation of the definitions of commonly used time-to-event endpoints, enabling
      appropriate comparisons of future trials' results.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is no methodology to provide appropriate definitions for survival endpoints. As such,
      including or excluding an event in a survival endpoint definition is only based on opinion
      from experts. For this reason, we launched the DATECAN-1 project in 2009. Its objective is to
      elaborate standardized definitions for survival endpoints in randomized clinical trials,
      based on a rigorous and validated consensus methodology. Once this project will be finalized
      (2012), guidelines for the definitions of survival endpoints to be used in clinical trials
      will be available.

      This collaborative work involves the network of the statisticians from Regional Comprehensive
      Cancer Centers (Bordeaux, Lille, Montpellier, Dijon, Paris, Toulouse), the network of the
      Cancer Data Centers (CTD) of the French National Cancer Institute (INCA; Montpellier,
      Bordeaux, Curie, Dijon-GERCOR) as well as the Headquarters from the European Organization for
      Research and Treatment of Cancer (EORTC). This project is supported by a 2009 grant from the
      French League Against Cancer .

      The DATECAN-1 project relies on a validated formal consensus method (Fitch K. The Rand/UCLA
      appropriateness method user's manual. 2001). This consensus approach formalizes the degree of
      agreement among experts by identifying and selecting the points on which experts agree,
      disagree or are undecided. The guidelines are subsequently based on agreement points. It is a
      rigorous and explicit method since it involves international experts in clinical trials in
      the field of the targeted cancer localizations. This method involves two rounds of rating
      (questionnaires) and an in-person meeting to address points for which consensus has not been
      reached yet.

      We published the methodology of the consensus process (Bellera et al. Eur J Cancer 2013).

      Guidelines have now been published following the international consensus process, for
      pancreatic cancer, sarcoma and GIST, beast cancer and renal cell carcinoma (See &quot;Citations
      filed&quot; below). For other localization (head and neck, stomach, colon): guidelines are
      ongoing.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 2009</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-specific survival</measure>
    <time_frame>1 year</time_frame>
    <description>To be defined by the consensus process</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>1 year</time_frame>
    <description>To be defined by the consensus process</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Loco-regional relapse free survival</measure>
    <time_frame>1 year</time_frame>
    <description>To be defined by the consensus process</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>1 year</time_frame>
    <description>To be defined by the consensus process</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>1 year</time_frame>
    <description>To be defined by the consensus process</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to local progression</measure>
    <time_frame>1 year</time_frame>
    <description>To be defined by the consensus process</description>
  </secondary_outcome>
  <number_of_groups>6</number_of_groups>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Sarcoma and GIST</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Breast cancer</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Pancreatic cancer</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Renal cell carcinoma</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Colon Cancer (adjuvant setting)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Solid tumours undergoing image-guided tumor ablation</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sarcoma and GIST</intervention_name>
    <description>No Intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.</description>
    <arm_group_label>Sarcoma and GIST</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Breast cancer</intervention_name>
    <description>No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.</description>
    <arm_group_label>Breast cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pancreatic cancer</intervention_name>
    <description>No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.</description>
    <arm_group_label>Pancreatic cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Renal cell carcinoma</intervention_name>
    <description>No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.</description>
    <arm_group_label>Renal cell carcinoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Colon cancer</intervention_name>
    <description>No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy (adjuvant setting).</description>
    <arm_group_label>Colon Cancer (adjuvant setting)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        No patient will be included.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sarcoma / GIST

          -  Breast cancer

          -  Pancreatic cancer

          -  Renal cell carcinoma

        Exclusion Criteria :

        - Individual patient data unavailable
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut du Cancer de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Bellera CA, Penel N, Ouali M, Bonvalot S, Casali PG, Nielsen OS, Delannes M, Litière S, Bonnetain F, Dabakuyo TS, Benjamin RS, Blay JY, Bui BN, Collin F, Delaney TF, Duffaud F, Filleron T, Fiore M, Gelderblom H, George S, Grimer R, Grosclaude P, Gronchi A, Haas R, Hohenberger P, Issels R, Italiano A, Jooste V, Krarup-Hansen A, Le Péchoux C, Mussi C, Oberlin O, Patel S, Piperno-Neumann S, Raut C, Ray-Coquard I, Rutkowski P, Schuetze S, Sleijfer S, Stoeckle E, Van Glabbeke M, Woll P, Gourgou-Bourgade S, Mathoulin-Pélissier S; Definition for the Assessment of Time-to-event Endpoints in Cancer Trials Initiative. Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†. Ann Oncol. 2015 May;26(5):865-72. doi: 10.1093/annonc/mdu360. Epub 2014 Jul 28. Review.</citation>
    <PMID>25070543</PMID>
  </results_reference>
  <results_reference>
    <citation>Bonnetain F, Bonsing B, Conroy T, Dousseau A, Glimelius B, Haustermans K, Lacaine F, Van Laethem JL, Aparicio T, Aust D, Bassi C, Berger V, Chamorey E, Chibaudel B, Dahan L, De Gramont A, Delpero JR, Dervenis C, Ducreux M, Gal J, Gerber E, Ghaneh P, Hammel P, Hendlisz A, Jooste V, Labianca R, Latouche A, Lutz M, Macarulla T, Malka D, Mauer M, Mitry E, Neoptolemos J, Pessaux P, Sauvanet A, Tabernero J, Taieb J, van Tienhoven G, Gourgou-Bourgade S, Bellera C, Mathoulin-Pélissier S, Collette L. Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). Eur J Cancer. 2014 Nov;50(17):2983-93. doi: 10.1016/j.ejca.2014.07.011. Epub 2014 Sep 22. Review.</citation>
    <PMID>25256896</PMID>
  </results_reference>
  <results_reference>
    <citation>Bellera CA, Pulido M, Gourgou S, Collette L, Doussau A, Kramar A, Dabakuyo TS, Ouali M, Auperin A, Filleron T, Fortpied C, Le Tourneau C, Paoletti X, Mauer M, Mathoulin-Pélissier S, Bonnetain F. Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials. Eur J Cancer. 2013 Mar;49(4):769-81. doi: 10.1016/j.ejca.2012.09.035. Epub 2012 Nov 2.</citation>
    <PMID>23122780</PMID>
  </results_reference>
  <results_reference>
    <citation>Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso MJ, Chibaudel B, Coleman R, Cufer T, Dal Lago L, Dalenc F, De Azambuja E, Debled M, Delaloge S, Filleron T, Gligorov J, Gutowski M, Jacot W, Kirkove C, MacGrogan G, Michiels S, Negreiros I, Offersen BV, Penault Llorca F, Pruneri G, Roche H, Russell NS, Schmitt F, Servent V, Thürlimann B, Untch M, van der Hage JA, van Tienhoven G, Wildiers H, Yarnold J, Bonnetain F, Mathoulin-Pélissier S, Bellera C, Dabakuyo-Yonli TS. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). Ann Oncol. 2015 Dec;26(12):2505-6. doi: 10.1093/annonc/mdv478. Epub 2015 Oct 13.</citation>
    <PMID>26467471</PMID>
  </results_reference>
  <results_reference>
    <citation>Kramar A, Negrier S, Sylvester R, Joniau S, Mulders P, Powles T, Bex A, Bonnetain F, Bossi A, Bracarda S, Bukowski R, Catto J, Choueiri TK, Crabb S, Eisen T, El Demery M, Fitzpatrick J, Flamand V, Goebell PJ, Gravis G, Houédé N, Jacqmin D, Kaplan R, Malavaud B, Massard C, Melichar B, Mourey L, Nathan P, Pasquier D, Porta C, Pouessel D, Quinn D, Ravaud A, Rolland F, Schmidinger M, Tombal B, Tosi D, Vauleon E, Volpe A, Wolter P, Escudier B, Filleron T; DATECAN Renal Cancer group. Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†. Ann Oncol. 2015 Dec;26(12):2392-8. doi: 10.1093/annonc/mdv380. Epub 2015 Sep 14. Review.</citation>
    <PMID>26371288</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 17, 2018</study_first_submitted>
  <study_first_submitted_qc>September 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2018</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Randomized controlled trial</keyword>
  <keyword>Endpoint</keyword>
  <keyword>Consensus</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

